FR2907006A1 - Cosmetic composition, useful in facial care, comprises allantoin, acetyl tetrapeptide-5 and a mixture of palmitoyl oligopeptide/palmitoyl tetrapeptide-7 - Google Patents
Cosmetic composition, useful in facial care, comprises allantoin, acetyl tetrapeptide-5 and a mixture of palmitoyl oligopeptide/palmitoyl tetrapeptide-7 Download PDFInfo
- Publication number
- FR2907006A1 FR2907006A1 FR0654317A FR0654317A FR2907006A1 FR 2907006 A1 FR2907006 A1 FR 2907006A1 FR 0654317 A FR0654317 A FR 0654317A FR 0654317 A FR0654317 A FR 0654317A FR 2907006 A1 FR2907006 A1 FR 2907006A1
- Authority
- FR
- France
- Prior art keywords
- palmitoyl
- tetrapeptide
- composition according
- amount
- oligopeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 title claims abstract description 32
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 title claims abstract description 22
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 title claims abstract description 22
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 title claims abstract description 21
- 229940093441 palmitoyl oligopeptide Drugs 0.000 title claims abstract description 21
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 title claims abstract description 18
- 239000002537 cosmetic Substances 0.000 title claims abstract description 18
- 229960000458 allantoin Drugs 0.000 title claims abstract description 17
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 title claims abstract description 16
- 230000001815 facial effect Effects 0.000 title claims abstract description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 6
- 239000003205 fragrance Substances 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000002304 perfume Substances 0.000 claims description 5
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 claims description 4
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 4
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 4
- 229920006037 cross link polymer Polymers 0.000 claims description 4
- 229940008099 dimethicone Drugs 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 4
- 229940031674 laureth-7 Drugs 0.000 claims description 4
- 239000010445 mica Substances 0.000 claims description 4
- 229910052618 mica group Inorganic materials 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical group CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 claims description 2
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 claims description 2
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 claims description 2
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 claims description 2
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 claims description 2
- 229920000299 Nylon 12 Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- 241000209140 Triticum Species 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 244000098338 Triticum aestivum Species 0.000 claims description 2
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 2
- 229940086555 cyclomethicone Drugs 0.000 claims description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 229940100608 glycol distearate Drugs 0.000 claims description 2
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 claims description 2
- 229940049290 hydrogenated coco-glycerides Drugs 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 2
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 229940094944 saccharide isomerate Drugs 0.000 claims description 2
- 229950011392 sorbitan stearate Drugs 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 229940098760 steareth-2 Drugs 0.000 claims description 2
- 229940100458 steareth-21 Drugs 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 229960000281 trometamol Drugs 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 108010091287 palmitoyl-glycyl-histidyl-lysine Proteins 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 1
- MDMNSAVSQAHVLC-MDTVQASCSA-N 2-aminoacetic acid;(2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCC(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CNC=N1 MDMNSAVSQAHVLC-MDTVQASCSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001503991 Consolida Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003501 anti-edematous effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
L'invention concerne une composition cosmétique comprenant deThe invention relates to a cosmetic composition comprising
l'allantoïne, de l'acétyl tétrapeptide-5, du palmitoyl oligopeptide et du palmitoyl tetrapeptide-7. L'invention trouve son application dans le domaine des soins cosmétiques en particulier pour le visage. De nombreux produits cosmétiques sont aujourd'hui proposés aux consommateurs. Les personnes souhaitant améliorer l'aspect de leur peau du visage vont appliquer plusieurs produits comme par exemple un anti-rides, un hydratant et un anti-poches. Cette utilisation de différents produits n'est ni io pratique, ni sûr car ces produits n'ont pas pour but d'être associés. Le document WO2005/048968 au nom de SEDERMA décrit une composition pharmaceutique ou cosmétique contenant un tripeptide et un tétrapeptide destiné au traitement des signes visibles de l'âge comme par exemples les rides. En particulier le tripeptide est le palmitoyl oligopeptide ou 15 complexe Pal-GHK et le tétrapeptide est le palmitoyl tetrapeptide-7 ou complexe Pal-GQPR. Le document WO2006/040374 au nom de LIPOTEC décrit l'acétyl tétrapeptide-5 et son utilisation pour réduire les poches sous les yeux. Par ailleurs l'allantoïne est couramment utilisée dans les soins 20 cosmétiques. Il apparaît le besoin de créer un soin cosmétique pour le visage ayant un effet général et améliorant la qualité de la peau du visage. La demanderesse a découvert de manière surprenante que l'acétyl tétrapeptide-5, le mélange de palmitoyl oligopeptide et de palmitoyl 25 tétrapeptide-7 et l'allantoïne ont des actions synergiques et que leur association dans un cosmétique permet une réduction des rides et des poches sous les yeux en augmentant l'hydratation. L'invention a pour objet une composition cosmétique à administration topique destinée au soin du visage caractérisée par le fait qu'elle comprend : de 30 l'allantoïne en quantité inférieure à 2% en poids, de l'acétyl tétrapeptide-5 en quantité inférieure à 0,1 % en poids, un mélange de palmitoyl oligopeptide/palmitoyl tétrapeptide-7, dans un rapport de 2 pour 1, en quantité inférieure à 0,001 %. allantoin, acetyl tetrapeptide-5, palmitoyl oligopeptide and palmitoyl tetrapeptide-7. The invention finds its application in the field of cosmetic care especially for the face. Many cosmetic products are now available to consumers. People wishing to improve the appearance of their facial skin will apply several products such as anti-wrinkle, moisturizer and anti-pockets. This use of different products is neither practical nor safe because these products are not intended to be associated. WO2005 / 048968 in the name of SEDERMA describes a pharmaceutical or cosmetic composition containing a tripeptide and a tetrapeptide for the treatment of visible signs of aging, for example wrinkles. In particular, the tripeptide is palmitoyl oligopeptide or Pal-GHK complex and the tetrapeptide is palmitoyl tetrapeptide-7 or Pal-GQPR complex. WO2006 / 040374 in the name of LIPOTEC describes acetyl tetrapeptide-5 and its use to reduce bags under the eyes. In addition, allantoin is commonly used in cosmetic care. It appears the need to create a cosmetic facial care having a general effect and improving the quality of the facial skin. The Applicant has surprisingly discovered that acetyl tetrapeptide-5, the mixture of palmitoyl oligopeptide and palmitoyl tetrapeptide-7 and allantoin have synergistic actions and that their combination in a cosmetic makes it possible to reduce wrinkles and puffiness. under the eyes by increasing hydration. The subject of the invention is a cosmetic composition for topical administration intended for the care of the face, characterized in that it comprises: of allantoin in an amount of less than 2% by weight, acetyl tetrapeptide-5 in a smaller quantity. at 0.1% by weight, a mixture of palmitoyl oligopeptide / palmitoyl tetrapeptide-7, in a ratio of 2 to 1, in an amount of less than 0.001%.
2907006 2 Avantageusement, le mélange de palmitoyl oligopeptide et de palmitoyl tétrapeptide-7 est composé d'une quantité de palmitoyl oligopeptide deux fois celle du palmitoyl tétrapeptide-7. L'allantoïne (5-Uréido-hydantoïne - C4H6N403) est présente à l'état 5 naturel dans la Grande Cousoude (Symphitum consolida Ledeb). Elle peut aussi être synthétisée par l'industrie. L'allantoïne est connue pour être un cicatrisant et un anti-irritant utilisé dans l'industrie cosmétique et pharmaceutique. L'acétyl tétrapeptide-5 (nom de l'International Nomenclature of io Cosmetic Ingredients : INCI) est un peptide possédant des propriétés antioedème. Il est commercialisé en France sous le nom commercial Eyeseryl par la société Lipotec. Ce composé est connu pour diminuer les poches sous les yeux et les cernes en augmentant l'élasticité et l'hydratation de la peau. Cependant, la 15 société Lipotec conseille d'utiliser entre 1 et 10% d"Eyeseryl dans les formulations pour obtenir un effet. Ce qui correspond à une quantité d'acétyl tétrapeptide-5 de 0,001 à 0,01 %. Le palmitoyl oligopeptide ou Pal-GHK est formé d'un tripeptide de glycine - histidine û lysine, greffé au niveau de la glycine sur un acide 20 gras saturé : le palmitoyl. Le palmitoyl tétrapeptide-7 ou Pal-GQPR est formé d'un tétrapeptide de glycine û glutamine û proline û arginine, greffé au niveau de la glycine sur un acide gras saturé : le palmitoyl. Le palmitoyl oligopeptide et le palmitoyl tetrapeptide-7 sont 25 commercialisés sous forme mélangée par la société Sederma sous le nom commercial de Matrixyl 3000 . Ce produit est connu pour être un anti-rides. Avantageusement, la composition cosmétique comprend : de l'allantoïne en quantité comprise entre 0,05% et 0,5% en poids, de l'acétyl tétrapeptide-5 en quantité comprise entre 0,0005% et 0,003% en poids, un 30 mélange de palmitoyl oligopeptide/palmitoyl tétrapeptide-7 (2/1) en quantité comprise entre 0,000001 % et 0,000006% en poids. Selon un mode de réalisation la composition cosmétique peut se présenter sous forme de crème.Advantageously, the mixture of palmitoyl oligopeptide and palmitoyl tetrapeptide-7 is composed of a quantity of palmitoyl oligopeptide twice that of palmitoyl tetrapeptide-7. Allantoin (5-Ureidohydantoin - C4H6N4O3) is present in the natural state in the Great Cousoude (Symphitum consolida Ledeb). It can also be synthesized by the industry. Allantoin is known to be a healing and an anti-irritant used in the cosmetic and pharmaceutical industry. Acetyl tetrapeptide-5 (name of the International Nomenclature of Cosmetic Ingredients: INCI) is a peptide with anti-edema properties. It is marketed in France under the trade name Eyeseryl by Lipotec. This compound is known to reduce puffiness and dark circles by increasing the elasticity and hydration of the skin. However, Lipotec recommends using between 1 and 10% of Eyeseryl in the formulations to achieve an effect, which corresponds to an amount of acetyl tetrapeptide-5 of 0.001 to 0.01%. Pal-GHK is composed of a glycine-histidine-lysine tripeptide grafted at the level of glycine on a saturated fatty acid: palmitoyl, palmitoyl tetrapeptide-7 or Pal-GQPR is formed of a glycine tetrapeptide - glutamine-proline-arginine, grafted to glycine on a saturated fatty acid: palmitoyl, palmitoyl oligopeptide and palmitoyl tetrapeptide-7 are marketed in the form mixed by Sederma under the trade name Matrixyl 3000. This product is known to be an anti-wrinkle Advantageously, the cosmetic composition comprises: allantoin in an amount of between 0.05% and 0.5% by weight, acetyl tetrapeptide-5 in an amount between 0.0005 % and 0.003% in weight s, a mixture of palmitoyl oligopeptide / palmitoyl tetrapeptide-7 (2/1) in an amount between 0.000001% and 0.000006% by weight. According to one embodiment, the cosmetic composition may be in the form of a cream.
2907006 3 Selon un autre mode de réalisation la composition cosmétique peut se présenter sous forme de lait. Selon un autre mode de réalisation la composition cosmétique peut se présenter sous forme de sérum.In another embodiment, the cosmetic composition may be in the form of milk. According to another embodiment, the cosmetic composition may be in the form of serum.
5 La composition cosmétique selon l'invention est destinée à une application topique sur le visage. II va être maintenant donné, à titre d'illustration et sans aucun caractère limitatif, diverses formulations de compositions selon l'invention. io Les pourcentages données sont des pourcentages en poids. Exemple I On illustre ici un exemple concret de formulation conforme à l'invention se présentant sous la forme d'une crème à usage topique : Nom des matières premières Pourcentage 15 Aqua QSP 100 Glycerin 12.000 Dipropyléne Glycol 5.000 Cyclomethicone 4.000 Nylon-12 4.000 20 Cyclopentasiloxane 3.800 Butyrospermum Parkii (Shea Butter) 3.000 Steareth-21 3.000 Saccharide Isomerate 2.097 Steareth-2 2.000 25 Conservateurs 0.800 Acrylates/C10-30 Alkyl Acrylate Crosspolymer 0.400 Allantoin 0.300 Parfum (Fragrance) 0.The cosmetic composition according to the invention is intended for topical application on the face. The following will now be given, by way of illustration and without any limiting nature, various formulations of compositions according to the invention. The percentages given are percentages by weight. Example I Here is illustrated a concrete example of a formulation according to the invention in the form of a cream for topical use: Name of the raw materials Percentage 15 Aqua QSP 100 Glycerin 12.000 Dipropylene Glycol 5.000 Cyclomethicone 4.000 Nylon-12 4.000 20 Cyclopentasiloxane 3.800 Butyrospermum Parkii (Shea Butter) 3.000 Steareth-21 3.000 Saccharide Isomerate 2.097 Steareth-2 2.000 25 Preservatives 0.800 Acrylates / C10-30 Alkyl Acrylate Crosspolymer 0.400 Allantoin 0.300 Perfume (Fragrance) 0.
300 Citric Acid 0.003 30 Acetyl Tetrapeptide-5 0.0022 Palmitoyl Oligopeptide 0.000002 Palmitoyl Tetrapeptide-7 0.000001 2907006 4 Exemple II On illustre ici un exemple concret de formulation conforme à l'invention se présentant sous la forme de lait à usage topique : Nom des matières premières Pourcentage 5 Aqua (Water) QSP 100 Paraffinum Liquidum (Minerai OH) 10.000 Polysorbate 60 3.500 Glycerin 3.000 Sorbitan Stearate 2.500 io Hydrogenated Coco-Glycerides 2.000 Cetearyl Isononanoate 1.000 Glycol Distearate 1.000 Dimethicone 1.000 Conservateurs 0.800 15 Parfum (Fragrance) 0.250 Acrylates/C10-30 Alkyl Acrylates Crosspolymer 0.200 Tromethamine 0.200 Polyacrylamide 0.200 Mica 0.140 20 Glycine Soja (Soybean) Oil 0.1245 Laureth-7 0.075 Allantoine 0.3000 Citric Acid 0.003 Acetyl Tetrapeptide-5 0.0022 25 Palmitoyl Oligopeptide 0.000002 Palmitoyl Tetrapeptide-7 0.000001 Exemple III On illustre ici un exemple concret de formulation conforme à l'invention se 30 présentant sous la forme de sérum à usage topique : Nom des matières premières Pourcentage Aqua (Water) QSP 100 Triticum Vulgare (Wheat) Protein 3.000 2907006 5 Glycerin PEG-8 Caprylic/Capric Triglyceride Ethoxydiglycol 5 Dimethicone Copolyol Polymethyl Methacrylate Polyacrylamide Conservateurs C13-14 Isoparaffin io Xanthan Gum Butylene Glycol Parfum (Fragrance) Mica Glycine Soja (Soybean) Oil 15 Laureth-7 Allantoine Citric Acid Acetyl Tetrapeptide-5 Palmitoyl Oligopeptide 20 Palmitoyl Tetrapeptide-7 3.000 3.000 2.000 2.000 1.000 0.750 0.600 0.800 0.300 0.250 0.150 0.150 0.140 0.1245 0.075 0.3000 0.003 0.0022 0.000002 0.000001 io300 Citric Acid 0.003 Acetyl Tetrapeptide-5 0.0022 Palmitoyl Oligopeptide 0.000002 Palmitoyl Tetrapeptide-7 0.000001 2907006 4 EXAMPLE II A concrete example of a formulation according to the invention in the form of topical milk is illustrated here: Name of raw materials Percentage 5 Aqua (Water) QSP 100 Paraffinum Liquidum (Ore OH) 10,000 Polysorbate 60 3,500 Glycerin 3,000 Sorbitan Stearate 2,500 io Hydrogenated Coco-Glycerides 2,000 Cetearyl Isononanoate 1,000 Glycol Distearate 1,000 Dimethicone 1,000 Preservatives 0.800 15 Perfume (Fragrance) 0.250 Acrylates / C10-30 Alkyl Acrylates Crosspolymer 0.200 Tromethamine 0.200 Polyacrylamide 0.200 Mica 0.140 20 Glycine Soybean Oil 0.1245 Laureth-7 0.075 Allantoin 0.3000 Citric Acid 0.003 Acetyl Tetrapeptide-0.0022 25 Palmitoyl Oligopeptide 0.000002 Palmitoyl Tetrapeptide-7 0.000001 Example III A concrete example of formulation according to the invention in the form of e serum for topical use: Name of raw materials Percentage Aqua (Water) QSP 100 Triticum Vulgare (Wheat) Protein 3.000 2907006 5 Glycerin PEG-8 Caprylic / Capric Triglyceride Ethoxydiglycol 5 Dimethicone Copolyol Polymethyl Methacrylate Polyacrylamide Preservatives C13-14 Isoparaffin io Xanthan Gum Butylene Glycol Perfume (Fragrance) Mica Glycine Soybean (Soybean) Oil 15 Laureth-7 Allantoin Citric Acid Acetyl Tetrapeptide-5 Palmitoyl Oligopeptide 20 Palmitoyl Tetrapeptide-7 3.000 3.000 2.000 1.000 0.750 0.600 0.800 0.300 0.250 0.150 0.150 0.140 0.1245 0.075 0.3000 0.003 0.0022 0.000002 0.000001 io
Claims (12)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0654317A FR2907006B1 (en) | 2006-10-17 | 2006-10-17 | COSMETIC COMPOSITION FOR FACIAL CARE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0654317A FR2907006B1 (en) | 2006-10-17 | 2006-10-17 | COSMETIC COMPOSITION FOR FACIAL CARE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2907006A1 true FR2907006A1 (en) | 2008-04-18 |
| FR2907006B1 FR2907006B1 (en) | 2008-12-12 |
Family
ID=38134828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0654317A Expired - Fee Related FR2907006B1 (en) | 2006-10-17 | 2006-10-17 | COSMETIC COMPOSITION FOR FACIAL CARE |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2907006B1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011026039A1 (en) * | 2009-08-28 | 2011-03-03 | Mary Kay Inc. | Skin care formulations |
| WO2018065918A1 (en) | 2016-10-04 | 2018-04-12 | Mary Kay Inc. | Methods and compositions for treating striae distensae |
| CN111110578A (en) * | 2020-02-26 | 2020-05-08 | 唐爱梅 | Anti-wrinkle essence with anti-wrinkle and anti-aging effects |
| CN114031668A (en) * | 2022-01-11 | 2022-02-11 | 浙江湃肽生物有限公司深圳分公司 | Acetyl tetrapeptide-5 analogue with anti-wrinkle effect and moisturizing peptide containing same |
| EP3990124A1 (en) * | 2019-06-28 | 2022-05-04 | L'Oréal | Anti-aging compositions and skin masks containing anti-aging compositions |
| PL442005A1 (en) * | 2022-08-11 | 2024-02-12 | Pan Drwal Spółka Z Ograniczoną Odpowiedzialnością | New compound, method of its preparation, composition and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060198800A1 (en) * | 2003-08-14 | 2006-09-07 | Natalie Dilallo | Skin care compositions including hexapeptide complexes and methods of their manufacture |
| DE102005063179A1 (en) * | 2005-12-30 | 2006-09-28 | Henkel Kgaa | Cosmetic or dermatological composition for topical skin treatment, used e.g. to increase epidermal thickness, contains a Vitamin B6 component and a compound that stimulates collagen synthesis |
-
2006
- 2006-10-17 FR FR0654317A patent/FR2907006B1/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060198800A1 (en) * | 2003-08-14 | 2006-09-07 | Natalie Dilallo | Skin care compositions including hexapeptide complexes and methods of their manufacture |
| DE102005063179A1 (en) * | 2005-12-30 | 2006-09-28 | Henkel Kgaa | Cosmetic or dermatological composition for topical skin treatment, used e.g. to increase epidermal thickness, contains a Vitamin B6 component and a compound that stimulates collagen synthesis |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11123578B2 (en) | 2009-08-28 | 2021-09-21 | Mary Kay Inc. | Skin care formulations |
| WO2011026039A1 (en) * | 2009-08-28 | 2011-03-03 | Mary Kay Inc. | Skin care formulations |
| CN102711721B (en) * | 2009-08-28 | 2013-09-25 | 玫琳凯公司 | Skin care formulations |
| EA023290B1 (en) * | 2009-08-28 | 2016-05-31 | Мэри Кей Инк. | Method of treating skin and topical composition for rejuvenating, replenishing and firming skin during sleep |
| US9833642B2 (en) | 2009-08-28 | 2017-12-05 | Mary Kay Inc. | Skin care formulations |
| US12097393B2 (en) | 2009-08-28 | 2024-09-24 | Mary Kay Inc. | Skin care formulations |
| US10434340B2 (en) | 2009-08-28 | 2019-10-08 | Mary Kay Inc. | Skin care formulations |
| US11679284B2 (en) | 2009-08-28 | 2023-06-20 | Mary Kay Inc. | Skin care formulations |
| CN102711721A (en) * | 2009-08-28 | 2012-10-03 | 玫琳凯公司 | Skin care formulations |
| US11596813B2 (en) | 2009-08-28 | 2023-03-07 | Mary Kay Inc. | Skin care formulations |
| WO2018065918A1 (en) | 2016-10-04 | 2018-04-12 | Mary Kay Inc. | Methods and compositions for treating striae distensae |
| EP3990124A1 (en) * | 2019-06-28 | 2022-05-04 | L'Oréal | Anti-aging compositions and skin masks containing anti-aging compositions |
| US11850298B2 (en) | 2019-06-28 | 2023-12-26 | L'oreal | Anti-aging compositions and skin masks containing anti-aging compositions |
| CN111110578A (en) * | 2020-02-26 | 2020-05-08 | 唐爱梅 | Anti-wrinkle essence with anti-wrinkle and anti-aging effects |
| CN114031668A (en) * | 2022-01-11 | 2022-02-11 | 浙江湃肽生物有限公司深圳分公司 | Acetyl tetrapeptide-5 analogue with anti-wrinkle effect and moisturizing peptide containing same |
| CN114031668B (en) * | 2022-01-11 | 2022-04-12 | 浙江湃肽生物有限公司深圳分公司 | Acetyl tetrapeptide-5 analogue with anti-wrinkle effect and moisturizing peptide containing same |
| PL442005A1 (en) * | 2022-08-11 | 2024-02-12 | Pan Drwal Spółka Z Ograniczoną Odpowiedzialnością | New compound, method of its preparation, composition and application |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2907006B1 (en) | 2008-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3622946B1 (en) | Cosmetic hair composition made of aloe vera and coconut oil and method for preparing same | |
| US20170216171A1 (en) | Biodegradable compositions comprising renewably-based, biodegradable 1,3-propanediol | |
| FR2907006A1 (en) | Cosmetic composition, useful in facial care, comprises allantoin, acetyl tetrapeptide-5 and a mixture of palmitoyl oligopeptide/palmitoyl tetrapeptide-7 | |
| WO2007095255A2 (en) | Biodegradable compositions comprising renewably-based, biodegradable 1.3-propanediol | |
| CN105640791A (en) | Antimicrobial compositions | |
| WO2007026101A1 (en) | Method of obtaining a plant extract from pome fruit, plant extract thus obtained and use of same | |
| WO2007144521A2 (en) | Cosmetic composition for topical use comprising wasabi | |
| JP2011020948A (en) | Cosmetic for skin or hair | |
| JP2024156049A (en) | Skin care formulations using lipophilic peptides | |
| EP1868632B1 (en) | Dermatological and/or cosmetic composition containing proteins of the sirt family | |
| FR3048611A1 (en) | ASSOCIATION OF ZANTHOXYLUM BUNGEANUM, BENTONITE, AND ACETYL HEXAPEPTIDE 8 FOR IMPROVING THE APPEARANCE OF THE SKIN. | |
| WO2021224575A1 (en) | Cosmetic composition comprising at least one calcareous red algae | |
| EP3801778B1 (en) | Use of a bixa orellana extract | |
| KR100814196B1 (en) | Skin external preparations and cosmetics containing inositol derivatives | |
| FR2958546A1 (en) | USE OF GLYCOPEPTIDES RICH IN SOYA HYDROXYPROLINE TO FIGHT THE APPEARANCE OF WRINKLES | |
| FR2759910A1 (en) | Cosmetic and dermo-pharmaceutical use of extracts of Kigelia africana | |
| FR3098115A1 (en) | Cosmetic formulation | |
| CN117205120B (en) | A wrinkle-resistant, firming and repairing cosmetic composition and its preparation method and application | |
| FR3006588A1 (en) | PEPTIDE SOYBEAN EXTRACT AND ITS COSMETIC USE TO STRENGTHEN THE STRUCTURE OF THE HAIR | |
| CH717634A2 (en) | Composition for topical application, for moisturizing the skin of diabetics, with the aim of promoting a reduction in the loss of hydration and skin aging, resulting from the phenomenon of glycation. | |
| JP2011153085A (en) | Cosmetic for preventing rough skin | |
| FR2667240A1 (en) | Active complex for dermocosmetic treatment products | |
| EP3126010A1 (en) | Cosmetic composition for lightening the skin | |
| Ścibisz et al. | Protein hydrolysates in cosmetics production, part II | |
| FR3127692A1 (en) | Solid COSMETIC composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |
Effective date: 20140630 |